Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C4H6O4S2 |
| Molecular Weight | 182.218 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)[C@@H](S)[C@@H](S)C(O)=O
InChI
InChIKey=ACTRVOBWPAIOHC-XIXRPRMCSA-N
InChI=1S/C4H6O4S2/c5-3(6)1(9)2(10)4(7)8/h1-2,9-10H,(H,5,6)(H,7,8)/t1-,2+
| Molecular Formula | C4H6O4S2 |
| Molecular Weight | 182.218 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Succimer is an analogue of dimercaprol, and has replaced dimercaprol as one of the main antidotes used in the management of poisoning by lead and other heavy metals. The advantages of succimer are that it is effective by oral administration because it is soluble in water, it is well-tolerated, has relatively low toxicity and can be given at the same time as iron supplements to treat iron deficiency anaemia. It does not cause significant increase in urinary excretion of essential minerals unlike the other widelyused lead chelating agent, sodium calcium EDTA.
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
55 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7588486/ |
10 mg/kg bw single, oral dose: 10 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
STIBOCAPTATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
25.3 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7716789/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUCCIMER plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
318 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7716789/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUCCIMER plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7588486/ |
10 mg/kg bw single, oral dose: 10 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
STIBOCAPTATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
9.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7716789/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUCCIMER plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2 day |
single, oral |
SUCCIMER blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| 2,3-Dimercaptopropanol, 2,3-dimercaptopropane-1-sulfonic acid, and meso-2,3-dimercaptosuccinic acid inhibit delta-aminolevulinate dehydratase from human erythrocytes in vitro. | 2004-03 |
|
| Reductions in blood lead overestimate reductions in brain lead following repeated succimer regimens in a rodent model of childhood lead exposure. | 2004-03 |
|
| Therapeutic potential of monoisoamyl and monomethyl esters of meso 2,3-dimercaptosuccinic acid in gallium arsenide intoxicated rats. | 2004-02-15 |
|
| Effect of succimer on growth of preschool children with moderate blood lead levels. | 2004-02 |
|
| Resistive index in febrile urinary tract infections: predictive value of renal outcome. | 2004-02 |
|
| Ultrasonography in the evaluation of renal scarring using DMSA scan as the gold standard. | 2004-02 |
|
| Combined efficacies of lipoic acid and 2,3-dimercaptosuccinic acid against lead-induced lipid peroxidation in rat liver. | 2004-01 |
|
| Reversal of cadmium induced oxidative stress by chelating agent, antioxidant or their combination in rat. | 2003-12-10 |
|
| Studies of urinary cystine precipitation in vitro: ontogeny of cystine nephrolithiasis and identification of meso-2,3-dimercaptosuccinic acid as a potential therapy for cystinuria. | 2003-12 |
|
| Interaction between metals and chelating agents affects glutamate binding on brain synaptic membranes. | 2003-12 |
|
| Successful ways to increase retention in a longitudinal study of lead-exposed children. | 2003-11 |
|
| Ascorbic acid supplementation does not improve efficacy of meso-dimercaptosuccinic acid treatment in lead-exposed suckling rats. | 2003-10 |
|
| Gunshot-induced plumbism in an adult male. | 2003-10 |
|
| Lead toxicosis in cats-a review. | 2003-10 |
|
| Analysis of meso-2,3-dimercaptosuccinic acid in human urine by capillary electrophoresis using direct injection. | 2003-10 |
|
| Reverse of the differential uptake intensity of Tc-99m MIBI and Tc-99m V-DMSA by multiple myeloma lesions in response to therapy. | 2003-08 |
|
| Succimer (meso-2,3-dimercaptosuccinic acid (DMSA)) treatment of Andean children with environmental lead exposure. | 2003-07-10 |
|
| Beneficial effect of combined administration of some naturally occurring antioxidants (vitamins) and thiol chelators in the treatment of chronic lead intoxication. | 2003-06-15 |
|
| Subcutaneous injection of metallic mercury. | 2003-06 |
|
| Effects of calcium disodium EDTA and meso-2,3-dimercaptosuccinic acid on tissue concentrations of lead for use in treatment of calves with experimentally induced lead toxicosis. | 2003-06 |
|
| Metal chelators change the human sperm motility pattern. | 2003-06 |
|
| Interaction of dimercaptosuccinic acid (DMSA) with angiotensin II on calcium mobilization in vascular smooth muscle cells. | 2003-05-15 |
|
| One-pot preparation of subnanometer-sized gold clusters via reduction and stabilization by meso-2,3-dimercaptosuccinic acid. | 2003-04-09 |
|
| Haematological, hepatic and renal alterations after repeated oral and intraperitoneal administration of monoisoamyl DMSA. II. Changes in female rats. | 2003-04-01 |
|
| Combined efficacies of lipoic acid and meso-2,3-dimercaptosuccinic acid on lead-induced erythrocyte membrane lipid peroxidation and antioxidant status in rats. | 2003-04 |
|
| Acute pyelonephritis and sequelae of renal scar in pediatric first febrile urinary tract infection. | 2003-04 |
|
| Comparison of relative renal function by renal scintigraphy and lateralized creatinine clearance in children with bilateral vesicoureteral reflux. | 2003-04 |
|
| Effects of dietary lead and/or dimercaptosuccinic acid exposure on regional serotonin and serotonin metabolite content in rainbow trout (Oncorhynchus mykiss). | 2003-03-20 |
|
| 2,3-Dimercaptopropane-1-sulfonic acid and meso-2,3-dimercaptosuccinic acid increase mercury- and cadmium-induced inhibition of delta-aminolevulinate dehydratase. | 2003-03-03 |
|
| Oral treatment of avian lead intoxication with meso-2,3-dimercaptosuccinic acid. | 2003-03 |
|
| The role of oxidative stress in the in vitro induction of micronuclei by pesticides in mouse lung fibroblasts. | 2003-03 |
|
| Functional evaluation by quantitative dimercaptosuccinic Acid scintigraphy after kidney trauma in children. | 2003-02 |
|
| Severe lead poisoning in pregnancy. | 2003-01-24 |
|
| The efficacy of monoisoamyl ester of dimercaptosuccinic acid in chronic experimental arsenic poisoning in mice. | 2003-01 |
|
| Chronic arsenic toxicity: clinical features, epidemiology, and treatment: experience in West Bengal. | 2003-01 |
|
| Symposium on radionuclides in paediatric nephro-urology. | 2003-01 |
|
| [Managing childhood lead poisoning]. | 2003 |
|
| Arsenic uptake by native fern species in Thailand: effect of chelating agents on hyperaccumulation of arsenic by Pityrogramma calomelanos. | 2003 |
|
| Vitamin C, glutathione, or lipoic acid did not decrease brain or kidney mercury in rats exposed to mercury vapor. | 2003 |
|
| [Metal poisoning]. | 2003 |
|
| A patient with postoperative mercury contamination of the peritoneum. | 2003 |
|
| Dimercaptosuccinic acid and Prussian Blue in the treatment of acute thallium poisoning in rats. | 2003 |
|
| Acute arsenic poisoning treated by intravenous dimercaptosuccinic acid (DMSA) and combined extrarenal epuration techniques. | 2003 |
|
| Mercury toxicity and antioxidants: Part 1: role of glutathione and alpha-lipoic acid in the treatment of mercury toxicity. | 2002-12 |
|
| Haematological, hepatic and renal alterations after repeated oral or intraperitoneal administration of monoisoamyl DMSA. I. Changes in male rats. | 2002-11-09 |
|
| Effect of meso-2,3-dimercaptosuccinic acid on urinary lead excretion in exposed men. | 2002-11 |
|
| The renal Na(+)-dependent dicarboxylate transporter, NaDC-3, translocates dimethyl- and disulfhydryl-compounds and contributes to renal heavy metal detoxification. | 2002-11 |
|
| Do children with falling blood lead levels have improved cognition? | 2002-10 |
|
| Reversal of lead-induced oxidative stress by chelating agent, antioxidant, or their combination in the rat. | 2002-09 |
|
| Anti microbial activity of dimercaptosuccinic acid (DMSA): a new chelating agent. | 2001-12 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:46:19 GMT 2025
by
admin
on
Mon Mar 31 18:46:19 GMT 2025
|
| Record UNII |
DX1U2629QE
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
1984
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
||
|
NDF-RT |
N0000175963
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
||
|
LIVERTOX |
NBK548099
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
||
|
NCI_THESAURUS |
C62357
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
4.2
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
||
|
FDA ORPHAN DRUG |
50790
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
||
|
NDF-RT |
N0000175962
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
||
|
FDA ORPHAN DRUG |
50890
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
304-55-2
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
PRIMARY | |||
|
206-155-2
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
PRIMARY | |||
|
2486
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201073
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
PRIMARY | |||
|
6783
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
PRIMARY | |||
|
C61953
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
PRIMARY | |||
|
3446
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID1023601
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
PRIMARY | |||
|
DB00566
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
PRIMARY | |||
|
m10265
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
PRIMARY | Merck Index | ||
|
D004113
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
PRIMARY | |||
|
SUB10663MIG
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
PRIMARY | |||
|
100000083487
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
PRIMARY | |||
|
4621
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
PRIMARY | |||
|
DX1U2629QE
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
PRIMARY | |||
|
SUB23276
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
PRIMARY | |||
|
DX1U2629QE
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
PRIMARY | |||
|
63623
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
PRIMARY | |||
|
2724354
Created by
admin on Mon Mar 31 18:46:19 GMT 2025 , Edited by admin on Mon Mar 31 18:46:19 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
